Clinical Trials
56 trialsKEYLYNK-001
Merck Sharp & Dohme LLC
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Laekna Limited
MK-4830-002
Merck Sharp & Dohme LLC
KEYVIBE-005
Merck Sharp & Dohme LLC
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Inspirna, Inc.
IVY
Eli Lilly and Company
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Canadian Cancer Trials Group
Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
Barbara Ann Karmanos Cancer Institute
Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer
University of Wisconsin, Madison
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
National Cancer Institute (NCI)
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
National Cancer Institute (NCI)
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
GOG Foundation
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Dana-Farber Cancer Institute
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
GOG Foundation
CatuNeo
AIO-Studien-gGmbH
Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer
GOG Foundation
IP
University of Louisville
Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
Masonic Cancer Center, University of Minnesota
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
Masonic Cancer Center, University of Minnesota
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
SWOG Cancer Research Network
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
GOG Foundation
Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
Hoosier Cancer Research Network
Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer
M.D. Anderson Cancer Center
Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
GOG Foundation
Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus
Memorial Sloan Kettering Cancer Center
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
University of Arizona
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
Duke University
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Sarcoma Alliance for Research through Collaboration
S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
SWOG Cancer Research Network
Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma
University of Southern California
Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer)
GOG Foundation
A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer
National Cancer Institute (NCI)
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer
National Cancer Institute (NCI)
Chemotherapy in Treating Patients With Solid Tumors
Memorial Sloan Kettering Cancer Center
Docetaxel in Treating Patients With Advanced Cancer of the Cervix
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors
National Cancer Institute (NCI)
Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer
University of California, Irvine
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
National Institutes of Health Clinical Center (CC)
Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies
Azaya Therapeutics, Inc.
TEACO
Sanofi
OCSTUD
Sanofi
Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer
Dana-Farber Cancer Institute
Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers
Montefiore Medical Center